A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors

Inclusion Criteria: * Written informed consent * Patients with confirmed advanced solid tumors. * No prior chemotherapy within 5 years of the diagnosis of SCLC (small cell lung cancer). * At least 4 weeks since last chemotherapy, radiotherapy, biologic therapy or surgery. * Laboratory criteria: Patients must have adequate bone marrow reserve and adequate kidney and liver function. Exclusion criteria: * Women who are pregnant or lactating. * Patients of child bearing potential refusing to practice adequate contraception. * Patients with uncontrolled vomiting. * Active infection. * Patients with clinical evidence of any gastrointestinal (GI) conditions which would alter GI absorption or GI motility. * Patients requiring treatment with cyclosporin A. * Severe medical problems other than the cancer, that would limit the ability of the patient to follow study guidelines or expose the patient to extreme risk. * Ongoing or planned chemotherapy, immunotherapy, radiotherapy, or investigational therapy for cancer treatment. * Use of investigational drug within 30 days prior to the first dose of study medication.